Chemomab Therapeutics Ltd. Accretion Expense
Chemomab Therapeutics Ltd. (CMMB) reported Accretion Expense of $638.00 thousand for the 12-month period ending 2022-12-31, per its 20-F filed 2026-03-23.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AccretionExpense · last filed 2026-03-23
| Period end | Accretion Expense 12 month |
|---|---|
| 2022-12-31 | $638.00K 20-F · filed 2026-03-23 |